je.st
news
Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars
2015-11-12 05:49:58| Biotech - Topix.net
Click this link to find out how much you can save.) Exelixis achieved a major milestone on Tuesday as the company's Cotellic was approved by the FDA as a treatment for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf. Cotellic has already been approved in Switzerland earlier this year.
Tags: call
investor
digest
biotech
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||